BPC-157 Dosing Guide: Subcutaneous vs Oral, Protocols, and Timing

BPC-157 Dosing Guide: Subcutaneous vs Oral, Protocols, and Timing

Key Takeaways:

• Animal research uses doses that extrapolate to roughly 200-500mcg per day in humans (body surface area calculation).
• Subcutaneous injection offers more predictable systemic bioavailability than oral administration.
• Oral administration may be preferable for gut-targeted applications due to direct mucosal contact.
• Injection near the injury site vs systemic injection is debated, with some evidence favoring local delivery.
• BPC-157 has no FDA-approved human dosing protocol. All dosing information is based on preclinical research.

Important: This content summarizes published preclinical research on a research compound. BPC-157 is not approved for human use by the FDA or any regulatory body. No standard human dosing protocol exists. This is not medical advice. See our full medical disclaimer.

---

Why Dosing Guidance for BPC-157 Is Complicated

Most pharmaceutical guides give you exact doses because regulators required clinical trials at specific doses before approving the drug. BPC-157 has never completed that process.

What we have instead is a large body of animal research, primarily in rats, conducted across dozens of studies using different doses, different administration routes, and different applications. Researchers and practitioners who work with BPC-157 extrapolate from that animal data using body surface area (BSA) calculations to estimate human-equivalent doses.

This is a reasonable scientific approach. It is also not the same thing as having actual human dosing data. The numbers below represent the best available inference from preclinical research, not clinically validated human protocols.

For a full review of what BPC-157 does and the research behind it, see our BPC-157 benefits guide.

---

The Dose Range: Where the Animal Research Points

Most BPC-157 animal studies fall into one of two general dose categories when converted to human-equivalent doses.

Lower range: 200-250mcg per day This is where many foundational studies land. A significant portion of the tendon, ligament, and GI research uses doses that convert to approximately 2-10mcg/kg in rats, which translates to roughly 200-250mcg for an average adult when using standard BSA conversion factors.

Higher range: 400-500mcg per day Some studies, particularly those looking at more severe tissue damage or combined applications, use higher doses that convert to the 400-500mcg range. A small number of studies go higher, but these represent the upper boundary of what the research literature supports.

Most community protocols based on this research settle in the 200-500mcg per day range as a working framework. Splitting into two doses (morning and evening) is a common approach to maintain more consistent levels throughout the day, though no research directly validates this practice in humans.

Using our dosage calculator can help you work through the BSA conversion math based on individual body weight if you want to replicate the research dosing approach more precisely.

---

Subcutaneous vs Oral BPC-157: Bioavailability Differences

The route of administration is one of the most important variables in BPC-157 research, and the answer is not one-size-fits-all.

Subcutaneous Injection

Subcutaneous injection delivers BPC-157 directly into the tissue just beneath the skin, bypassing the digestive tract entirely. This is generally considered the more bioavailable route for systemic applications. The compound enters the bloodstream without exposure to the acidic environment of the stomach or the enzymatic activity of the intestines.

For applications targeting musculoskeletal tissue, neurological effects, or systemic repair, subcutaneous injection is the standard in animal research and the most commonly referenced route in the practitioner community.

The tradeoff is practicality. Subcutaneous injection requires proper technique, sterile equipment, and reconstituted peptide. For people new to peptide research, the learning curve is real.

Oral BPC-157 (Capsules or Liquid)

The conventional assumption is that oral peptides are degraded in the stomach before reaching systemic circulation. BPC-157 research complicates this.

Multiple animal studies on gut-specific applications have used oral administration and found significant results. This suggests that, at minimum, orally administered BPC-157 reaches the GI mucosa in active form before substantial degradation occurs. The stomach and upper intestinal lining are directly exposed, which is mechanistically relevant for gut healing applications.

Whether meaningful amounts of orally administered BPC-157 reach systemic circulation (bloodstream, muscle, tendon) is less clear. The evidence for systemic effects via oral administration is weaker than for injection.

The practical implication: if the target is gut healing, oral administration has reasonable research support. If the target is a shoulder tendon, subcutaneous injection is the better-supported route.

For a deep dive on the gut-specific research, see our BPC-157 gut healing guide.

---

Injection Near Injury vs Systemic Injection

This is one of the more debated questions in BPC-157 practice, and the research does not definitively resolve it.

The Case for Local Injection

Some animal studies have administered BPC-157 via intramuscular or subcutaneous injection directly at or near the injury site. The rationale is that higher local concentrations might accelerate repair at the specific tissue. A 2010 study on Achilles tendon repair found significant effects using local injection protocols (PMID: 21030672). A study on ligament healing reported similar findings with local administration (PMID: 20225319).

The Case for Systemic (Remote) Injection

Other studies have administered BPC-157 at sites far from the injury and still found tissue repair effects. This suggests systemic circulation is sufficient, and local injection may not be necessary.

One explanation is that BPC-157's primary mechanisms, nitric oxide modulation and growth factor upregulation, are systemic. Once in circulation, the compound may preferentially act where tissue damage and inflammatory signaling are occurring, regardless of where it was injected.

The practical reality for most people researching BPC-157 for musculoskeletal applications: injecting near the injury site is common practice, informed by the local-injection research. But the systemic evidence suggests that getting BPC-157 into circulation matters more than pinpoint injection accuracy.

---

Timing: AM vs PM, Fasted vs Fed

There is essentially no human research on timing optimization for BPC-157. What exists is extrapolation and community observation.

Morning vs Evening

No animal study has directly compared morning vs evening administration and found a meaningful difference. BPC-157 does not appear to have circadian-dependent mechanisms the way some hormonal peptides do.

Many practitioners default to morning dosing for practical reasons, taking it with their morning peptide or supplement routine. Split dosing (half in the morning, half in the evening) is common when using the higher end of the dose range.

Fasted vs Fed

For subcutaneous injection, whether you have eaten does not affect the compound's entry into the bloodstream. This is a non-issue for injected BPC-157.

For oral BPC-157, the situation is different. Taking it away from food (fasted, or at least not immediately after a large meal) may reduce competition with digestive enzymes and gastric acid, potentially preserving more active compound for mucosal contact. This is mechanistically plausible but not directly studied.

---

Cycle Length: What the Research Suggests

Animal studies have used protocols ranging from a few days to 8-12 weeks. No research has established an optimal cycle length for humans.

Community consensus, drawn from practitioner observation rather than controlled trials, generally lands in a few common patterns:

• Acute protocol (injury-specific): 4-8 weeks for a specific tissue repair goal, then discontinue.
• GI protocol: 4-6 weeks, with re-evaluation.
• Cycling approach: 8-12 weeks on, followed by a break of comparable length before resuming if needed.

The rationale for cycling is precautionary. No long-term human safety data exists for BPC-157, and cycling is a conservative approach to managing unknown long-term exposure risks.

---

Reconstitution Basics

BPC-157 is typically sold as a lyophilized (freeze-dried) powder. It must be reconstituted with bacteriostatic water before injection.

The general reconstitution process:

1. Add bacteriostatic water to the vial using a sterile syringe, injecting it slowly down the side of the vial, not directly onto the powder.
2. Allow the powder to dissolve without shaking. Gentle swirling is acceptable.
3. Calculate your per-dose volume based on the total peptide amount in the vial and your target dose.
4. Store reconstituted peptide refrigerated. Most sources recommend use within 4-6 weeks once reconstituted.

Our reconstitution calculator handles the math: enter your vial amount (in mcg), water volume added, and target dose to get the exact volume to draw per injection.

For a more detailed walkthrough of the reconstitution process, see our guide on how to reconstitute peptides.

---

Common Mistakes

Using the wrong water. Only bacteriostatic water should be used for reconstitution. Sterile water for injection can work but has no preservative, shortening shelf life significantly. Tap water is not acceptable.

Shaking the vial. Peptides are sensitive to mechanical stress. Swirl gently, do not shake.

Incorrect dose math. If a vial contains 5mg (5000mcg) and you add 2.5mL of bacteriostatic water, each 0.1mL drawn contains 200mcg. Getting this math wrong is the most common dosing error. Use the reconstitution calculator.

Poor storage. Lyophilized powder should be stored in a cool, dry place away from light, ideally refrigerated. Reconstituted peptide must be refrigerated and used within the recommended timeframe.

Expecting immediate results. Animal studies show tissue repair over weeks, not days. Community reports suggest the same. Expecting dramatic effects within a few days of starting is unrealistic based on the research.

Ignoring sourcing quality. The quality of research peptides varies significantly by vendor. Independent third-party testing certificates of analysis (COA) are the minimum standard for verifying purity and concentration.

---

Side Effects and Safety Profile

BPC-157 has a notably mild reported side effect profile in animal research. No animal studies have identified significant toxicity at doses within the standard research range.

The most commonly reported community side effects are nausea (particularly with oral administration on an empty stomach), mild headache, and transient dizziness. These are generally reported as dose-dependent and manageable.

Long-term safety data for BPC-157 in humans does not exist. The absence of reported toxicity in animal studies is reassuring but does not substitute for human trials. This is a research compound with an incomplete safety profile by definition.

---

How BPC-157 Compares to the TB-500 Stack for Dosing

BPC-157 is frequently used alongside TB-500 (Thymosin Beta-4) for combined tissue repair protocols. Dosing approaches differ between the two compounds.

TB-500 is typically used at lower frequency (2-4mg once or twice per week, often with a loading phase) compared to BPC-157's daily dosing approach. The two compounds target different mechanisms, making them complementary rather than redundant.

For full details on how these two peptides work together and how practitioners structure combined protocols, see our BPC-157 and TB-500 stack guide.

---

FAQ

What is the standard BPC-157 dose? No standard human dose exists. Animal research converts to approximately 200-500mcg per day using body surface area calculations. This is the range most commonly referenced in research contexts.

Should I inject BPC-157 near the injury or anywhere? Both local and systemic injection have shown effects in animal studies. Local injection near the injury site is common practice, but the systemic evidence suggests location may matter less than getting the compound into circulation.

Can I take BPC-157 orally instead of injecting? Oral administration is viable for gut-targeted applications based on animal research. For musculoskeletal or neurological applications, subcutaneous injection is the better-supported route due to higher systemic bioavailability.

How long should a BPC-157 cycle be? Animal studies range from days to 12 weeks. Community consensus for human research protocols typically runs 4-8 weeks for acute applications, with cycling breaks before resuming if needed.

Does BPC-157 need to be refrigerated? Lyophilized powder should be stored cool and dry. Reconstituted BPC-157 must be refrigerated and used within 4-6 weeks.

---

Sources

1. Sikiric P, et al. "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Curr Pharm Des. 2018;24(18):1990-2001. PMID: 29898181
2. Pevec D, et al. "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Med Sci Monit. 2010;16(3):BR81-88. PMID: 21030672
3. Staresinic M, et al. "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth." J Orthop Res. 2003;21(6):976-983. PMID: 20225319

---

Related reading:

• BPC-157 Benefits: What the Research Actually Shows
• BPC-157 for Gut Healing
• BPC-157 and TB-500 Stack for Recovery
• BPC-157 Compound Page
• Dosage Calculator
• Reconstitution Calculator

---

This article is for informational and educational purposes only. It does not constitute medical advice. BPC-157 is not FDA-approved for human use. No human clinical trials have established safe or effective dosing. Do not use this information to diagnose or treat any medical condition. Always consult a qualified healthcare provider before considering research compounds. See our full disclaimer.